MAPK3 and hepatocellular carcinoma: HMGB1 promotes HCC resistance to sorafenib by stimulating the downstream MAPK cascade through Erk1/2 phosphorylation, activating autophagy, and eventually inhibiting cancer cell apoptosis [30].